Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 176 Colorectal Neoplasms 153 Rectal Neoplasms 122 Stomach Neoplasms 112 Pancreatic Neoplasms 60 Neoplasm Metastasis 60 Colonic Neoplasms 42 Triple Negative Breast Neoplasms 34 Neoplasms 29 Esophageal Neoplasms 28 Cholangiocarcinoma 17 Biliary Tract Neoplasms 17 Nasopharyngeal Carcinoma 16 Gallbladder Neoplasms 16 Carcinoma, Hepatocellular 16 Adenocarcinoma 16 Locally Advanced Rectal Cancer 15 Squamous Cell Carcinoma of Head and Neck 10 Head and Neck Neoplasms 10 Esophageal Squamous Cell Carcinoma 10 Brain Neoplasms 10 Bile Duct Neoplasms 10 Adenocarcinoma Of Esophagus 10 Liver Neoplasms 9 Gastrointestinal Neoplasms 9 Breast Neoplasms, Male 9 Neuroendocrine Tumors 7 Colorectal Cancer Metastatic 7 Carcinoma, Renal Cell 7 Ovarian Neoplasms 6

Interventions

pasireotide 4 Temozolomide 2 lutetium Lu 177 dotatate 1 farletuzumab 1 antineoplaston AS 2-1 1 antineoplaston A10 1 Tranexamic Acid 1 Thyrotropin-Releasing Hormone 1 TBR-760 1 Rosiglitazone 1 Nivolumab 1 Microarray Analysis 1 Lapatinib 1 Ipilimumab 1 DNA Methylation 1 Complementary Therapies 1 Capecitabine 1 Cabergoline 1 Biological Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pituitary Neoplasms × Capecitabine × Clear all

NCT03930771 2022-08-09

TMZ-Cap

Weill Medical College of Cornell University

Phase 2 Terminated

1 enrolled 8 charts

Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡